3 Cardiac Brands, Pain Care Portfolio and Custom Synthesis Stocks With a Strong Future Roadmap: Torrent Pharmaceuticals, Ipca Laboratories and Divi’s Laboratories
- October 21, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Torrent Pharmaceuticals, Ipca Laboratories and Divi’s Laboratories: ROE of 14.2% to 25.5% and FY22 to FY26 revenue CAGR of 5.1% to 13.6%. Prices as of 20 Oct 2026.
Quick Answer
The three pharma brand and ingredient stocks to watch are Torrent Pharmaceuticals, Ipca Laboratories and Divi’s Laboratories. Their return on equity ranges from 14.2% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 13.6%. Torrent Pharmaceuticals has the highest return on equity at 25.5%, while Ipca Laboratories has the fastest revenue growth at 13.6% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Pharma brand and ingredient stocks cover both ends of the medicine chain, from the products doctors prescribe to the active ingredients that go inside them. Torrent Pharmaceuticals, Ipca Laboratories and Divi’s Laboratories offer a cardiac and central nervous system brand leader, a pain and anti-malarial portfolio with in-house ingredients, and a large custom synthesis supplier.
This list covers three pharma brand and ingredient stocks with complete current figures: Torrent Pharmaceuticals, Ipca Laboratories and Divi’s Laboratories. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma Brand and Ingredient Stocks?
Pharma brand and ingredient stocks are listed companies that either sell finished medicines to patients through doctors or supply the active ingredients and intermediates that other drug makers need. Brand sellers depend on prescriptions, while ingredient makers depend on long-term supply contracts and plant capacity.
Pharma Brand and Ingredient Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Torrent Pharmaceuticals | 4,558.7 | 173,079 | 80.3 | 36.0 | 25.5 | 1.79 |
| Ipca Laboratories | 1,814.5 | 46,050 | 33.5 | 36.0 | 14.2 | 0.10 |
| Divi’s Laboratories | 9,087 | 241,311 | 82.5 | 36.0 | 15.3 | 0.00 |
On valuation, Ipca Laboratories trades at a P/E below the industry P/E, while Torrent Pharmaceuticals and Divi’s Laboratories trade above it, which reflects the growth the market already expects. Readers comparing pharma brand and ingredient stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pharma brand and ingredient stocks can use the coming numbers to test whether growth is holding.
Why Do Pharma Brand and Ingredient Stocks Have a Strong Roadmap in India?
Pharma brand and ingredient stocks have a strong roadmap in India because domestic medicine demand is growing steadily while global drug makers are looking for dependable Indian partners for supply.
- Chronic therapy demand. Heart, brain and metabolic conditions create repeat prescriptions.
- Backward integration. Making ingredients in-house supports quality and cost control.
- Global supply chains. Large drug makers prefer long-term suppliers with proven plants and compliance.
Why Torrent Pharmaceuticals Features Among These Pharma Brand and Ingredient Stocks
Among the pharma brand and ingredient stocks on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.
In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%.
Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.
Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.
Why Ipca Laboratories Features Among These Pharma Brand and Ingredient Stocks
Among the pharma brand shares on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.
Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore.
Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.
Why Divi’s Laboratories Features Among These Pharma Brand and Ingredient Stocks
Among the three companies on this list, Divi’s Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.
Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%.
In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.
Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.
What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.
Torrent Pharmaceuticals vs Ipca Laboratories vs Divi’s Laboratories on Key Financials
The table below sets the three pharma brand and ingredient stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals | 8,705 | 13,886 | 12.4% | 2,138 | 15.4% |
| Ipca Laboratories | 5,896 | 9,821 | 13.6% | 1,191 | 12.1% |
| Divi’s Laboratories | 9,074 | 11,067 | 5.1% | 2,568 | 23.2% |
Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Ipca Laboratories shows the fastest revenue growth with a 13.6% compound annual rate. A useful habit with pharma brand and ingredient stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several API maker stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Torrent Pharmaceuticals | 3,141 | 4,909 | 56.3% |
| Ipca Laboratories | 2,342 | 2,813 | 20.2% |
| Divi’s Laboratories | 2,529 | 3,144 | 24.3% |
Key Risks to Check Before Investing in Pharma Brand and Ingredient Stocks
Every theme carries risks that deserve a check before any decision. For these pharma brand and ingredient stocks, the main points are: Long-term pharma brand shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Input costs. Raw material and solvent prices can move margins in a quarter.
- Customer concentration. Custom synthesis revenue depends on a limited set of global customers.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma brand and ingredient stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma Brand and Ingredient Stocks
Pharma brand and ingredient stocks suit investors who want exposure across the medicine chain. Torrent Pharmaceuticals, Ipca Laboratories and Divi’s Laboratories each have a defined strength and visible capacity or portfolio plans. Based on the 20 October 2026 close, Torrent Pharmaceuticals trades at Rs 4,558.7, Ipca Laboratories at Rs 1,814.5 and Divi’s Laboratories at Rs 9,087. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma brand and ingredient stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma brand and ingredient stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma brand and ingredient stocks?
Ans. Pharma brand and ingredient stocks are listed companies that either sell finished medicines to patients through doctors or supply the active ingredients and intermediates that other drug makers need. Brand sellers depend on prescriptions, while ingredient makers depend on long-term supply contracts and plant capacity. This list looks at three of them, Torrent Pharmaceuticals, Ipca Laboratories and Divi’s Laboratories, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which pharma brand and ingredient stocks are covered in this list?
Ans. This list covers Torrent Pharmaceuticals, Ipca Laboratories and Divi’s Laboratories. Based on the 20 October 2026 close, Torrent Pharmaceuticals traded at Rs 4,558.7, Ipca Laboratories at Rs 1,814.5 and Divi’s Laboratories at Rs 9,087. Their return on equity ranges from 14.2% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 13.6%.
Why do pharma brand and ingredient stocks have a strong future roadmap in India?
Ans. Pharma brand and ingredient stocks have a strong roadmap in India because domestic medicine demand is growing steadily while global drug makers are looking for dependable Indian partners for supply. The main drivers are as follows. Chronic therapy demand. Heart, brain and metabolic conditions create repeat prescriptions. Backward integration. Making ingredients in-house supports quality and cost control. Global supply chains. Large drug makers prefer long-term suppliers with proven plants and compliance. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Torrent Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.
How has Ipca Laboratories performed financially?
Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.
How has Divi’s Laboratories performed financially?
Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.
What risks should investors check before buying pharma brand and ingredient stocks?
Ans. Investors should check a few risks before buying pharma brand and ingredient stocks. Input costs. Raw material and solvent prices can move margins in a quarter. Customer concentration. Custom synthesis revenue depends on a limited set of global customers. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma brand and ingredient stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
